ADNI Biomarker Core: A review of progress since 2004 and future challenges

by Clinical Neuropsychologist | Saturday, November 30, 2024 | Dementia

Abstract BACKGROUND We describe the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Biomarker Core major activities from October 2004 to March 2024, including biobanking ADNI cerebrospinal fluid (CSF), plasma, and serum biofluid samples, biofluid analyses for...

The detection of GRN mutation carriers by progranulin blood protein levels from finger‐stick collection

by Clinical Neuropsychologist | Saturday, November 30, 2024 | Dementia

Abstract INTRODUCTION Heterozygous mutations in the progranulin gene (GRN) leading to decreased progranulin levels are one of the most frequent causes of inherited frontotemporal dementia (FTD). We evaluated progranulin levels in dried blood spots from capillary...

Sex differences in the trajectories of plasma biomarkers, brain atrophy, and cognitive decline relative to amyloid onset

by Clinical Neuropsychologist | Friday, November 29, 2024 | Dementia

Abstract INTRODUCTION The factors that influence the progression of Alzheimer’s disease (AD) after individuals become amyloid-positive are poorly understood. This study examines how sex influences the longitudinal trajectories of plasma AD and neurodegenerative...

Communication Bridge‐2 randomized controlled trial: Recruitment and baseline features

by Clinical Neuropsychologist | Tuesday, November 26, 2024 | Dementia

Abstract INTRODUCTION Non-pharmacological interventions may offer significant benefits to the quality of life for persons with primary progressive aphasia (PPA) and their care partners but have lacked efficacy trials. To help fill the efficacy gap, we provide the...

Elevated locus coeruleus metabolism provides resilience against cognitive decline in preclinical Alzheimer’s disease

by Clinical Neuropsychologist | Tuesday, November 26, 2024 | Dementia

Abstract INTRODUCTION Alterations in locus coeruleus’ (LC) metabolic turnover are associated with Alzheimer’s disease (AD)-pathology and cognitive impairment. However, the evolution of these changes across disease stages and their functional relevance remains...

The Consortium for Clarity in ADRD Research Through Imaging (CLARiTI)

by Clinical Neuropsychologist | Tuesday, November 26, 2024 | Dementia

Abstract The presence of multiple pathologies is the largest predictor of dementia. A major gap in the field is the in vivo detection of mixed pathologies and their antecedents. The Alzheimer’s Disease Research Centers (ADRCs) are uniquely positioned to address...